IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.283
EU - Europa 1.415
AS - Asia 225
AF - Africa 3
OC - Oceania 3
SA - Sud America 2
Totale 8.931
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.279
IE - Irlanda 419
SE - Svezia 236
IT - Italia 204
UA - Ucraina 202
DE - Germania 160
SG - Singapore 138
GB - Regno Unito 82
IN - India 50
FR - Francia 45
CN - Cina 24
BE - Belgio 16
FI - Finlandia 14
RU - Federazione Russa 13
CA - Canada 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
HK - Hong Kong 4
JP - Giappone 4
NL - Olanda 4
AU - Australia 3
KR - Corea 3
EE - Estonia 2
HR - Croazia 2
ZA - Sudafrica 2
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
LT - Lituania 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
Totale 8.931
Salva come PNG Salva come JPEG
Città #
Des Moines 1.770
Chandler 1.018
Fairfield 535
Jacksonville 455
Ashburn 428
Dublin 417
Houston 325
Woodbridge 248
Wilmington 245
Cambridge 216
Seattle 200
Lawrence 163
Princeton 163
San Mateo 142
Ann Arbor 123
Boardman 102
Redmond 87
San Diego 65
Washington 60
New York 58
Pune 49
Los Angeles 42
London 25
Centro 19
Brussels 16
Falls Church 13
Kilburn 13
Norwalk 13
Beijing 12
Cedar Knolls 12
Helsinki 12
Rome 11
Shenzhen 7
Milan 6
New Bedfont 6
Prescot 6
Squinzano 6
Turin 6
Hounslow 5
Marano Vicentino 4
Pescara 4
Redwood City 4
Wandsworth 4
Amsterdam 3
Civitanova Marche 3
Islington 3
Istia D'ombrone 3
San Gregorio da Sassola 3
Vallefoglia 3
Central 2
Edinburgh 2
Gatchina 2
Genoa 2
Hong Kong 2
Kyoto 2
Moscow 2
Napoli 2
Paris 2
Prague 2
Southwark 2
St Petersburg 2
Tallinn 2
Wuhan 2
Alba 1
Ancona 1
Asunción 1
Athens 1
Belgrade 1
Bolzano 1
Boston 1
Brdo 1
Burnaby 1
Callao 1
Catford 1
Cellamare 1
Chengdu 1
Chicago 1
Chiswick 1
Dallas 1
Damanhur 1
Faisalabad 1
Falkenstein 1
Fayetteville 1
Figline Valdarno 1
Formigine 1
Greenwich 1
Hangzhou 1
Hanover 1
Irvine 1
Jesi 1
Johannesburg 1
Kingston 1
Madrid 1
Marseille 1
Melbourne 1
Monsampolo del Tronto 1
Muizenberg 1
Mönchengladbach 1
Nuremberg 1
Oslo 1
Totale 7.198
Salva come PNG Salva come JPEG
Nome #
Idiopathic anaphylaxis 171
Diagnosing, managing and preventing anaphylaxis: Systematic review 131
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 121
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 109
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 106
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 97
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 95
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 94
In vivo diagnosis of allergic diseases - allergen provocation tests 93
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 91
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 91
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 90
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 85
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 84
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 82
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 80
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 79
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 78
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 78
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 78
Anaphylaxis 78
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 76
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 76
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 74
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 74
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 74
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 73
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 73
Contraindications to immunotherapy: A global approach 72
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 72
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 72
Diagnosis of Hymenoptera venom allergy 72
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 71
The natural history and epidemiology of insect venom allergy: clinical implications 71
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 70
The role of component-resolved diagnosis in Hymenoptera venom allergy 70
Advances in Hymenoptera venom immunotherapy 70
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 70
Mast cell diseases and the severity and course of intraoperative anaphylaxis 69
EAACI anaphylaxis guidelines: Systematic review protocol 69
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 68
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 67
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 66
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 66
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 66
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 66
Risk Factors and Characteristics of Biphasic Anaphylaxis 66
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 64
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 64
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 63
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 63
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 63
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 62
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 61
World Allergy Organization anaphylaxis guidelines: Summary 61
Congruence between international guidelines and mite specific immunotherapy prescribing practices 61
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 61
Purified vs. nonpurified venom immunotherapy 61
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 61
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 61
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 60
Hymenoptera Venom Allergy - European Academy of Allergy and Clinical Immunology Monographs 60
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 60
Use of adrenaline in allergy 60
Treating venom allergy during COVID-19 pandemic 60
Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ? 59
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity 59
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 59
International consensus on (ICON) anaphylaxis 59
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 59
Epidemiology of hymenoptera allergy 59
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 58
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 58
Oxytocin: an unexpected risk for cardiologic and broncho-obstructive effects, and allergic reactions in susceptible delivering women 58
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 57
High long-term efficacy of venom immunotherapy after discontinuation 57
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 57
First European data from the network of severe allergic reactions (NORA) 57
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 56
European Polistes venom allergy 56
Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice 56
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 55
Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register 54
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 54
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 54
Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy Reply 54
Lysozyme, a new allergen in donkey's milk 53
Honeybee venom immunotherapy: certainties and pitfalls 53
Component resolved diagnosis in real life: the risk assessment of food allergy using microarray-based immunoassay 53
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 52
Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? Reply 52
Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study 52
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 51
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 51
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry 51
Adherence to the rhinitis management plan of allergic rhinitis 51
Vespid allergy 51
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 51
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 51
Research needs in allergy: an EAACI position paper, in collaboration with EFA 51
Totale 6.868
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.869
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201947 0 0 0 0 0 0 0 0 0 0 45 2
2019/2020558 8 4 8 3 51 96 33 8 51 6 122 168
2020/20212.127 116 179 260 87 430 113 114 180 191 143 221 93
2021/20221.200 61 235 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.192 268 39 119 139 223 271 23 46 7 53 4 0
Totale 9.203